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Introduction {#sec005}
============

Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by a vast proliferation of immature myeloid blasts that accumulate in the bone marrow and blood. AML is closely correlated to cytokine networks of proliferation, differentiation and apoptosis of leukemic cells \[[@pone.0199689.ref001]\]. AML is caused by different factors including radiation, mutations and carcinogens \[[@pone.0199689.ref002]--[@pone.0199689.ref005]\]. The disease can progress quickly and can become fatal in a short period of time without treatment. Known prognostic factors of AML include age, mutations, complex karyotype, the antecedent hematologic disease, presence of elevated white blood cell counts and prior chemo or radiotherapy for another malignancy \[[@pone.0199689.ref006]\]. Intensive chemotherapy is initially effective in most patients with AML, however, the surviving LIC clones repopulate the disease and lead to subsequent disease relapse and poor prognosis \[[@pone.0199689.ref007]\]. In addition, the treatment of elderly patients and patients with relapsed refractory remains a challenge \[[@pone.0199689.ref008]--[@pone.0199689.ref010]\]. Therefore, an improved understanding of the molecular mechanisms underlying of AML could be helpful to improve the treatment efficacy to prolong the survival time for patients.

DNA methylation is an important epigenetic mechanism in regulating gene expression \[[@pone.0199689.ref011]\]. It is pointed out that epigenetic disturbances have been involved in the pathogenesis of leukemia \[[@pone.0199689.ref012]\]. Jiang Y et al found that progression from myelodysplastic syndrome to AML was correlated to increased aberrant DNA methylation \[[@pone.0199689.ref013]\]. Previous studies have investigated genome-wide methylation in AML \[[@pone.0199689.ref014]\]. In AML, the presence of common methylation patterns in *p15* and E-cadherin has been described \[[@pone.0199689.ref015], [@pone.0199689.ref016]\]. In addition, methylation of secreted frizzled related protein (*sFRP)1*, *sFRP12*, *sFRP13* and *sFRP15* with corresponding transcriptional silencing has been found in AML cell lines \[[@pone.0199689.ref017]\]. The survival analysis showed that GATA binding protein 4 (*GATA4*) promoter methylation was significantly associated with shorter overall survival of pediatric AML \[[@pone.0199689.ref018]\]. Thus it can be seen that DNA methylation may play a crucial role in the development of AML. In this study, we aimed to find potential survival-related DNA methylation signature in AML, which may pave the way for the development of novel tumor markers and therapeutic targets for AML.

Materials and methods {#sec006}
=====================

DNA methylation data retrieval and analysis {#sec007}
-------------------------------------------

DNA methylation data were downloaded from the TCGA dataset (<http://tcga-data.nci.nih.gov/tcga>). The data was derived from blood of AML. Among which, there were 195 samples with DNA methylation information. There were 188 samples with follow-up information. Finally, we selected 182 samples with both DNA methylation information and follow-up information. In order to improve data accuracy, the DNA methalytion sites were first preprocessed. DNA methalytion sites on sex chromosomes were excluded. Considering the heterogeneity of blood, based on the DNA methylation data, blood components were then predicted using the R packages in RefFreeEWAS. Finally, all samples were divided into the training group (127 cases) and validation group (55 cases) randomly. There were no overlapped cases between two groups. The chi-square test and t-test were used to analyze the statistical difference of clinical index between the two groups. And there was no significant difference in age, race, gender, vital status, survival time and disease risk result between the two groups. The clinical characteristics of these two groups were shown in [Table 1](#pone.0199689.t001){ref-type="table"}.

10.1371/journal.pone.0199689.t001

###### The clinical characteristics for training group and validation group.

![](pone.0199689.t001){#pone.0199689.t001g}

  Clinical index                                         Training group (n = 127)   Validation group (n = 55)   P value
  ------------------------- ---------------------------- -------------------------- --------------------------- -----------
  **Age**                   **Mean ± SD**                55.28346±16.05244          55.65455±16.52632           0.8886992
  **Median**                59                           58                                                     
  **Race**                  **Asia, Black or African**   1                          1                           0.4152429
  **American**              6                            5                                                      
  **White**                 119                          48                                                     
  **NA**                    1                            1                                                      
  **Gender**                **Female**                   54                         29                          0.268031
  **Male**                  73                           26                                                     
  **Vital status**          **Alive**                    50                         14                          0.1017496
  **Dead**                  77                           41                                                     
  **Survival time**         **Mean ± SD**                543.4724± 601.9671         570.3091 ±539.5071          0.7667396
  **Median**                334                          365                                                    
  **Disease risk**          **Favorable**                26                         9                           0.7268791
  **Intermediate/Normal**   73                           33                                                     
  **Poor**                  25                           13                                                     

NA: Not applicable.

Identification of survival related DNA methylation sites {#sec008}
--------------------------------------------------------

In order to select the survival associated DNA methylation sites, all DNA methylation sites were analyzed by the single factor Cox proportional hazard (CoxPH) regression after adjustment of age, race, gender, blood constituent and cytogenetic risk. Similarly, after further adjustment of age, race, gender, blood constituent and cytogenetic risk, the multi-factor CoxPH regression analysis was used for identification of DNA methylation signature in the survival evaluation. The statistical significance was set at p\<0.001. In order to investigate the characteristic of DNA methylation signature, the Illumina Infinium HumanMethylation450 BeadChips Assay was utilized for DNA methylation sites annotation.

Functional analysis of survival related DNA methylation signature genes {#sec009}
-----------------------------------------------------------------------

In order to study the biological function of survival-related DNA methylation signature genes, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed by using the online software GeneCodis3 (<http://genecodis.cnb.csic.es/analysis>). And the threshold of false discovery rate (FDR) \< 0.05 was set as the criteria of statistical significance.

Survival time analysis of DNA methylation signature in the training group and validation group {#sec010}
----------------------------------------------------------------------------------------------

The risk score (RS) of identified DNA methylation signature was calculated by the following equation: $$Risk\mspace{2mu} Score\mspace{2mu}(RS) = \sum\limits_{i = 1}^{N}\mspace{2mu}(M\text{eth}_{i}*C_{i})$$ N presents the number of DNA methylation; Methi presents the spectrum of ith DNA methylation site; Ci represents regression coefficient of ith DNA methylation site in the multi-factor CoxPH regression analysis. Kaplan-Meier survival curves were drawn and compared among subgroups using log-rank tests.

In addition, the receiver operating characteristic (ROC) analysis was performed to assess the 5 years' survival value of DNA methylation signature by using pROC package in R language. The area under the curve (AUC) under binomial exact confidence interval was calculated and the ROC curve was generated.

Identification of risk related DNA methylation sites {#sec011}
----------------------------------------------------

In order to identify the risk-related DNA methylation sites between patients with poor-risk (38 cases) and favorable-risk (35 cases), the related DNA methylation data were downloaded. We selected CpG sites based on differential methylation value calculated as mean (β case) − mean (β normal) (Δβ) combined with the false discovery rate (FDR) values. Finally, the threshold of \|Δβ\|\>0.2 and FDR\<0.05 was set as the [criteria](http://www.iciba.com/criteria) of statistical significance.

Results {#sec012}
=======

Survival related DNA methylation signature {#sec013}
------------------------------------------

After original data preprocess, a total of 3884 DNA methylation sites were identified in the training group. These DNA methylation sites were used for the single factor and multi-factor CoxPH regression analysis. The result showed that 8 DNA methylation sites were identified. 8 DNA methylation sites were located in 4 CpG islands (chr12:81102034--81102716, chr17:78863569--78863813, chr3:10183305--10183941 and chr6:29600192--29600661) and 6 genes (*MYF6*, *RPTOR*, *MMP10*, *SH3PXD2B*, *VHL* and *GABBR1*). The annotation of 8 DNA methylation sites was shown in [Table 2](#pone.0199689.t002){ref-type="table"}.

10.1371/journal.pone.0199689.t002

###### The annotation of 8 DNA methylation sites.
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  Site         Strand   Gene         Gene context      CpG island                 CpG island context
  ------------ -------- ------------ ----------------- -------------------------- --------------------
  cg26400830   F                                                                  
  cg20171297   R        *MYF6*       1stExon; 5\'UTR   chr12:81102034--81102716   N_Shore
  cg09891288   R        *RPTOR*      Body; Body        chr17:78863569--78863813   Island
  cg02061229   R        *MMP10*      Body                                         
  cg19979108   R        *SH3PXD2B*   Body                                         
  cg20916523   R        *VHL*        Body; Body        chr3:10183305--10183941    S_Shore
  cg21644740   F        *GABBR1*     Body; Body        chr6:29600192--29600661    N_Shore
  cg26182859   R                                                                  

Functional annotation of survival related DNA methylation signature genes {#sec014}
-------------------------------------------------------------------------

In order to further study the biological function of survival-related DNA methylation signature genes (*MYF6*, *RPTOR*, *MMP10*, *SH3PXD2B*, *VHL* and *GABBR1*), GO and KEGG functional annotation were performed. The result showed that only 2 GO terms were obtained. Protein binding was the most significantly enriched molecular function (FDR = 0.0103025) involving *RPTOR*, *VHL* and *SH3PXD2B*; cytoplasm (FDR = 0.00664319) was the most significantly enriched cellular component involving *RPTOR*, *GABBR1*, *VHL* and *SH3PXD2B*. Enriched GO terms of survival related DNA methylation signature genes were shown in [Table 3](#pone.0199689.t003){ref-type="table"}.

10.1371/journal.pone.0199689.t003

###### Enriched GO terms of survival related DNA methylation signature genes.
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  Items        Items_Details          P value      FDR          Genes
  ------------ ---------------------- ------------ ------------ -----------------------------------
  GO:0005515   protein binding (MF)   0.00515125   0.0103025    *RPTOR*,*VHL*,*SH3PXD2B*
  GO:0005737   cytoplasm (CC)         0.00664319   0.00664319   *RPTOR*,*GABBR1*,*VHL*,*SH3PXD2B*

FDR: false discovery rate

MF: molecular function

CC: cellular component

Survival time analysis of DNA methylation signature {#sec015}
---------------------------------------------------

In order to explore the association between the risk score and identified DNA methylation signature, the clustering analysis map of methylation value in the DNA methylation signature sites was performed ([Fig 1](#pone.0199689.g001){ref-type="fig"}). In the risk score calculation, the patients were dichotomized into either low risk or the high risk group. In the training group, a highly significant difference was observed between the high risk and the low risk group (p = 1.1e-06), which was shown in [Fig 2](#pone.0199689.g002){ref-type="fig"}. When the same DNA methylation signature equation was applied to the validation group, a similar significant difference was also observed between the high risk and the low risk group (p = 0.054), which was shown in [Fig 3](#pone.0199689.g003){ref-type="fig"}. Additionally, we performed 5 years' survival analysis of DNA methylation signature by ROC and calculated the AUC to assess the discriminatory ability of DNA methylation signature in the training and validation group, respectively (Figs [4](#pone.0199689.g004){ref-type="fig"} and [5](#pone.0199689.g005){ref-type="fig"}). The AUC of the DNA methylation signature in the training group was 0.8441558, and the validation was 0.8170732. Our result suggested that the DNA methylation signature could be the prognosis model for predicting the survival situation of AML.

![The clustering analysis map of methylation value in the DNA methylation signature sites.\
Diagram presents the result of a two-way hierarchical clustering of DNA methylation sites and risk score. The clustering is constructed using the complete-linkage method together with the Euclidean distance. Each row represents a DNA methylation site, and each column, a risk score value. The risk score clustering tree is shown on the right. The colour scale illustrates the relative value of the risk score: red, below the reference channel; green, higher than the reference.](pone.0199689.g001){#pone.0199689.g001}

![Kaplan-Meier curves showing AML patients dichotomized based on risk score in the training group.\
High risk is defined as a risk score ≥ the median, and low risk is defined as a risk score \< the median in the training group.](pone.0199689.g002){#pone.0199689.g002}

![Kaplan-Meier curves showing AML patients dichotomized based on risk score in the validation group.\
High risk is defined as a risk score ≥ the median, and low risk is defined as a risk score \< the median in the validation group.](pone.0199689.g003){#pone.0199689.g003}

![5 years' ROC curves of DNA methylation signature in the training group.\
The ROC curves were used to show the diagnostic ability of DNA methylation signature with 1-Specificity and sensitivity. The x-axis shows 1-specificity and y-axis shows sensitivity.](pone.0199689.g004){#pone.0199689.g004}

![5 years' ROC curves of DNA methylation signature in the validation group.\
The ROC curves were used to show the diagnostic ability of DNA methylation signature with 1-Specificity and sensitivity. The x-axis shows 1-specificity and y-axis shows sensitivity.](pone.0199689.g005){#pone.0199689.g005}

Identification of risk related DNA methylation sites {#sec016}
----------------------------------------------------

In order to identify the DNA methylation sites between patients with poor-risk and favorable-risk, the differentially methylated sites and CpG islands were analyzed based on the threshold of \|Δβ\|\>0.2 and FDR\<0.05. The result showed that 70 differentially methylated sites (64 hypermethylation and 6 hypomethylation sites) and 6 differentially methylated CpG islands (3 hypermethylation and 3 hypomethylation CpG islands) were identified. The top 20 differentially methylated sites in the poor-risk and favorable-risk group were shown in [Table 4](#pone.0199689.t004){ref-type="table"}.

10.1371/journal.pone.0199689.t004

###### The top 20 differentially methylated sites in the poor-risk and favorable-risk group.

![](pone.0199689.t004){#pone.0199689.t004g}

  Site         Gene          Island                      Δβ            FDR
  ------------ ------------- --------------------------- ------------- -------------
  cg27321949   *LRPAP1*      chr4:3516456--3516844       0.597435476   4.82581E-17
  cg04857395   *LRPAP1*      chr4:3516456--3516844       0.603433175   4.82581E-17
  cg25278298   *MAEA*        chr4:1303490--1303835       0.41009799    6.33572E-17
  cg24973755   *MAEA*        chr4:1304768--1305114       0.539319729   6.33572E-17
  cg06466348   *ADCY7*                                   0.529336818   4.87433E-16
  cg09936008   *ZNF213*      chr16:3190765--3191389      0.522768451   3.94334E-15
  cg01360627   *TNF*         chr6:31548436--31549277     0.556695472   5.62805E-15
  cg18349022   *ZNF498*                                  0.574523405   6.55958E-15
  cg13458384   *SARDH*       chr9:136567684--136568146   0.410375297   1.34354E-14
  cg17741993   *TNF*         chr6:31548436--31549277     0.587861991   1.34354E-14
  cg25197194   *CCDC48*                                  0.55303526    3.2255E-14
  cg26996656                                             0.558266306   3.37347E-14
  cg17427926   *LOC283999*   chr17:76228110--76228380    0.468902001   8.05456E-14
  cg02340818   *KIAA1688*    chr8:145806258--145806713   0.480393004   9.56514E-14
  cg06250720                                             0.483657658   1.96516E-13
  cg11227278   *KLHL29*      chr2:23749086--23749291     0.509376312   
  cg17115419                                             0.493501781   
  cg27049094   *HK2*                                     0.567439864   
  cg01824603   *ARHGEF10*                                0.511145159   
  cg25605731   *CALR*        chr19:13056458--13057125    0.588599806   

Δβ: mean (β case) − mean (β normal)

FDR: false discovery rate

Discussion {#sec017}
==========

AML is the most common form of adult leukemia and the survival rate is very low \[[@pone.0199689.ref019]--[@pone.0199689.ref021]\]. Therefore, it is urgent to understand the pathological mechanism and find potential survival related genes in the development of AML. In this study, we found a DNA methylation signature involving *MYF6*, *RPTOR*, *MMP10*, *SH3PXD2B*, *VHL* and *GABBR1*, which could be a valuable tool in guiding treatment decisions for AML.

Myogenic factor 6 (*MYF6*, also called MRF4 or Herculin) is expressed in skeletal muscle and is related to myogenesis \[[@pone.0199689.ref022]--[@pone.0199689.ref025]\]. It is found that the *MYF6* is a differentially methylation gene in plasma cf-DNA in the different stage of hepatocellular carcinoma development \[[@pone.0199689.ref026]\]. In addition, the methylation frequency of *MYF6* in stage I non-small cell lung cancer is obviously higher than that of non-cancerous lung disease control, which suggested that *MYF6* could offer a specificity and a sensitivity in the stage I non-small cell lung cancer diagnosis \[[@pone.0199689.ref027]\]. Thus it can be seen that *MYF6* methylation was associated with the development of cancer. In this study, we first found the DNA methylation of *MYF6* in the blood of AML. Our result showed that *MYF6* was significantly associated with survival time of AML and could be a diagnostic and prognostic marker of AML.

Regulatory associated protein of MTOR complex 1 (*RPTOR*) is a signal transduction gene important for hematopoiesis \[[@pone.0199689.ref028]\]. *RPTOR*, mechanistic target of rapamycin kinase and MTOR associated protein (mTOR), LST8 homolog (MLST8) constitute the core subunits of the mammalian TORC1 complex which play an important role in controlling cell growth, survival and metabolism and is often deregulated in cancer \[[@pone.0199689.ref029]--[@pone.0199689.ref032]\]. It is reported that *RPTOR* is hypermethylated in human hepatocytes \[[@pone.0199689.ref033]\]. Previous reports have demonstrated that *RPTOR* is methylated gene in breast tumors \[[@pone.0199689.ref034], [@pone.0199689.ref035]\]. This suggested that *RPTOR* methylation may play an important role in the process of cancer. In the present study, we found that *RPTOR* was methylated in the blood of AML and significantly associated with the survival time of AML patients. Our result suggested that *RPTOR* played a crucial role in AML and may be a diagnostic and prognostic marker in the process of AML.

Matrix metallopeptidase 10 (MMP10), an enzyme promoting angiogenesis, promotes cell growth and invasion, and exerts anti-apoptotic property in vitro \[[@pone.0199689.ref036], [@pone.0199689.ref037]\]. It is noted that MMP10 is essential to the tumor microenvironment. In colorectal cancer, MMP10 is up-regulated in cancerous tissue and adversely associated with patients survival \[[@pone.0199689.ref038], [@pone.0199689.ref039]\]. In cutaneous melanoma, *MMP10* is potentially modified by modification of histone acetylation \[[@pone.0199689.ref040]\]. In head and neck squamous cell cancer, *MMP10* is a differentially methylated gene in radiation-sensitive and -resistant tumors \[[@pone.0199689.ref041]\]. In immature teratomas, reduced methylation of *MMP10* significantly enriched in axonal guidance signaling pathway \[[@pone.0199689.ref042]\]. Previous reports indicated that the epigenomics changes of *MMP10*, especially DNA methylation may be involved in the occurrence of cancer. Herein, we found the methylation of *MMP10* in the blood of AML. Moreover, *MMP10* was related to the survivability of AML patients. Our result may provide a new field in the diagnosis and prognosis of AML.

SH3 and PX domains 2B (SH3PXD2B) is associated with growth and production. It is found that SH3PXD2B is involved in the protein binding, cytoplasm and cell junction in hepatocellular carcinoma \[[@pone.0199689.ref043]\]. In addition, *SH3PXD2B* positively regulates the differentiation of fat cell and shows differences in DNA methylation in gene body or intergenic region \[[@pone.0199689.ref044], [@pone.0199689.ref045]\]. However, there are no reports about the relationship between *SH3PXD2B* methylation and cancer. In this study, we first found methylated *SH3PXD2B* in the blood of AML. Moreover, it was observably associated with the survival time of AML patients. In a word, *SH3PXD2B* may play a crucial role in AML and could be a diagnostic and prognostic marker in the development of AML.

The gene product of the Von Hippel-Lindau tumor suppressor (*VHL*) plays a key role in regulation of metabolic genes expression, erythropoiesis, angiogenesis, proliferation and apoptosis. VHL-associated tumors are highly vascularized and overproduce VEGF \[[@pone.0199689.ref046]\]. It is indicated that *VHL* promoter hypermethylation may play an important role in pheochromocytoma and abdominal paraganglioma development \[[@pone.0199689.ref047]\]. Herman and Zhong et al found that *VHL* was a methylated gene in renal carcinoma cell lines \[[@pone.0199689.ref048], [@pone.0199689.ref049]\]. Hypomethylation of *VHL* has been reported in head and neck cancer and lung squamous carcinoma \[[@pone.0199689.ref050], [@pone.0199689.ref051]\]. Thus, *VHL* functions as a methylated gene in different cancers. It is pointed out that the mutations in the *VHL* gene are involved in the pathogenesis of AML \[[@pone.0199689.ref046]\]. Herein, we also found the relationship between *VHL* and AML. Our result showed that *VHL* was methylated and was significantly associated with survival time of AML patients.

Gamma-aminobutyric acid type B receptor subunit 1 (*GABBR1*) encodes the G protein-coupled receptor that can form the heterodimer with GABAB receptor 2, which triggering the proliferation, differentiation and migration of cancer cells. It is showed that multiple loci of *GABBR1* within 6p21.3 are related to nasopharyngeal carcinoma \[[@pone.0199689.ref052], [@pone.0199689.ref053]\]. *GABBR1* is a different methylated gene in plasma cf-DNA in different early stage of hepatocellular carcinoma development \[[@pone.0199689.ref026]\]. In addition, *GABBR1* is associated with the survival time of patients with gastric cancer \[[@pone.0199689.ref054]\]. It is also a survival-associated methylation marker for oral squamous cell carcinoma \[[@pone.0199689.ref055]\]. Thus it can be seen that *GABBR1* methylation play a crucial role in various cancers. In the present study, we found that *GABBR1* was methylated and associated with AML survival. It suggested that *GABBR1* may be a survival-associated methylation marker for AML.

Previous studies have reported that the 5-year survival rate was 55% for patients with favorable cytogenetics, 24% for patients with intermediate risk, and 5% for patients with poor-risk cytogenetics \[[@pone.0199689.ref056]\]. Thus it can be seen that the survival time was associated with AML risk. In this study, we identified numbers of survival-associated differentially methylated genes such as *LRPAP1*, *MAEA* and *TNF* between poor-risk and favorable-risk patients.

LDL receptor related protein associated protein 1 (*LRPAP1*) is a gene that involved in the cell proliferation in cancer \[[@pone.0199689.ref057]\]. It is noted that *LRPAP1* is a biologically relevant gene found in leukemia and was associated with different biological processes including cell apoptosis, signaling pathway and cell cycle checkpoint \[[@pone.0199689.ref058], [@pone.0199689.ref059]\]. Macrophage erythroblast attacher (MAEA) is a 36-kD transmembrane protein that expressed by erythroblasts and macrophage cells and plays a crucial role in hematopoiesis \[[@pone.0199689.ref060], [@pone.0199689.ref061]\]. It is reported that *MAEA* is a differentially methylated gene in Type-2 diabetes and idiopathic pulmonary fibrosis \[[@pone.0199689.ref062], [@pone.0199689.ref063]\]. Tumor necrosis factor (TNF) is a proinflammatory cytokine. It has been identified that TNF is elevated in serum of patients with aplastic anemia and myelodysplastic syndromes, suggesting that the hematopoietic repressive activity of TNF may contribute to the cytopenic phenotype of these patients \[[@pone.0199689.ref064]--[@pone.0199689.ref067]\]. Interestingly, TNF levels are significantly higher in the peripheral blood of AML patients of M3, M4, and M5 subtypes when compared with healthy donors \[[@pone.0199689.ref068]\]. Furthermore, the increased level of TNF is associated with poor prognosis of patients with AML, especially older adults \[[@pone.0199689.ref007], [@pone.0199689.ref069]--[@pone.0199689.ref071]\]. Our result further indicated the important role of *LRPAP1*, *MAEA* and *TNF* in AML.

Conclusions {#sec018}
===========

In a word, we have identified and successfully validated a DNA methylation signature in patients with AML. This signature adds to the potential predictive role in the survival time of AML patients. Utilization of a prognostic DNA methylation signature would enrich for potentially sensitive patients, thereby improving clinical outcome for future patients with AML. However, there is a limitation to our study. In the present study, we didn't perform the deeper mechanism study based on the identified methylated genes. Some animal model and cell experiments are further needed to explore the potential mechanism of AML.
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